Clinical Trial Update: Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder [Phase 1]

View source ↗

Summary

Open-label Phase I study evaluating hCT-MSC therapy in toddlers with Autism Spectrum Disorder has completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• hCT-MSC (human cord tissue-derived mesenchymal stem cells)

Snippet

Sponsor: Duke University | Conditions: Autism Spectrum Disorder | Phase 1 | Status: COMPLETED | Results posted: 2025-02-24